月経前症候群治療薬市場：薬物タイプ、種類、流通チャネル別-世界予測2024-2030年

月経前症候群治療薬市場規模は2023年に17億2,000万米ドルと推計され、2024年には17億9,000万米ドルに達し、CAGR 4.35％で2030年には23億2,000万米ドルに達すると予測されます。

月経前症候群（PMS）は、女性の月経周期の数週間前に起こる身体的、精神的、感情的な変化や症状の範囲からなります。症状は女性によって大きく異なり、日常生活や生活の質に大きな影響を与えます。そのため、PMSの治療は多面的かつ個別的であり、特定の症状を緩和し、全体的な幸福感を向上させることを目的としています。ライフスタイルの調整、食生活の改善、ストレス管理から薬理学的介入まで、その範囲は多岐にわたる。PMSとそれが女性の健康と幸福に与える影響についての認識と教育が高まり、月経の健康と幸福に対する社会的な考え方が変化したことで、包括的な治療法の必要性が高まっています。医学研究の進歩は、より効果的で個別化された治療につながり、遠隔医療サービスを含むヘルスケア・インフラとアクセシビリティの改善を促進する政府の支援は、より多くの女性が治療を受けることを促しています。しかし、新しい治療法や既存の治療法を取り巻く規制上のハードルや安全性への懸念は、PMS治療の普及を妨げる可能性があります。さらに、PMSの症状や治療効果にはばらつきがあるため、標準化された治療は難しいです。しかし、主な企業は、個々の遺伝的要因、ホルモン要因、生活習慣要因に合わせた治療法を開発し、副作用の少ない効果的な自然療法、食事療法、生活習慣への介入を研究しています。症状の追跡、治療、治療計画のためのデジタル・プラットフォームやアプリの作成は、女性のPMS治療オプションの採用をさらに後押しすることができる、

薬剤の種類避妊と症状管理の二重の役割により、PMS症状管理に経口避妊薬の利用が増加

鎮痛薬、特に非ステロイド性抗炎症薬（NSAIDs）は、PMSに伴う身体的不快感や痛みを緩和するために一般的に使用されるため、PMSの薬理学的治療において不可欠な要素です。これらの薬は、炎症や痛みを引き起こす物質として知られるプロスタグランジンの産生を阻害することにより、けいれん、乳房の圧痛、筋肉痛を軽減するのに有効です。選択的セロトニン再取り込み阻害薬（SSRI）は、PMS管理に処方される著名な抗うつ薬であり、特に感情や気分に関連する症状を対象としています。SSRIは、気分や社会的行動に影響を与える神経伝達物質である脳内のセロトニン濃度を増加させる。SSRIは、PMSの極端な形態である重度の月経前不快気分障害（PMDD）を経験している女性に特に有用であり、いらいら、気分の落ち込み、抑うつ、不安の軽減に有効であることが示されています。PMSやPMDDの治療には、経口避妊薬（避妊ピル）や卵巣抑制薬がよく用いられます。これらの薬は、排卵を調節または抑制することによって作用し、その結果、PMS症状の引き金となるホルモンの変動を抑制します。経口避妊薬は、エストロゲンとプロゲスチンを併用することで、ホルモンバランスを整え、身体的・精神的症状の重症度を軽減します。一方、ゴナドトロピン放出ホルモン（GnRH）作動薬は、卵巣ホルモンの産生を著しく低下させる別のクラスの卵巣抑制薬であり、PMDDの重症例にしばしば使用されます。

流通チャネル：便利なショッピングを求める顧客のニーズにより、eコマース流通チャネルが好まれるようになっています。

eコマース・プラットフォームは、月経前症候群（PMS）治療薬の重要な流通チャネルとして台頭してきました。このチャネルは、世界中で利用可能な幅広いPMS治療オプションへの容易なアクセスを容易にします。顧客は、自宅に居ながらにして製品を閲覧・購入できる利便性を高く評価しています。さらに、eコマース・プラットフォームは、多くの場合、詳細な製品情報、レビュー、比較を提供し、消費者が十分な情報を得た上で意思決定できるよう支援します。目立たないように製品を購入し、受け取ることができるため、PMS治療の選択肢を求める個人にとって、このチャネルの魅力が高まっています。小売薬局は、依然としてPMS治療薬の重要な流通チャネルです。この伝統的なチャネルでは、消費者は市販薬（OTC）や処方箋薬を簡単に手に入れることができます。薬剤師は、専門的なアドバイスを提供し、質問に答え、PMS症状を管理するための推奨事項を提示することで、重要な役割を果たしています。製品がすぐに手に入り、ヘルスケア専門家との個人的なやり取りができる小売薬局は、多くの人にとって好ましい選択肢となっています。さらに、小売薬局は幅広い製品を在庫していることが多く、様々な患者の嗜好や治療要件に対応しています。

地域別インサイト

南北アメリカでは、米国とカナダがPMS治療の主要国であり、高い認知度と医薬品・医療分野の研究開発に力を入れていることが特徴です。米国は、市販薬（OTC）、処方薬、天然サプリメントなど、治療アプローチの多様性が特徴で、個人の選択とホリスティックな健康を重視する国柄を表しています。南北アメリカ諸国では、PMSの追跡・管理用モバイルアプリなど、デジタルヘルスソリューションへの投資が続いています。EU諸国は、エビデンスに基づく医療を強く嗜好しており、自然療法や代替療法への関心が高まっています。遺伝子検査を活用してPMS治療をカスタマイズする個別化医療への動向も顕著です。EUにおける医療機器、製剤、医薬品の開発と効率化に関する厳しい規制は、EU地域におけるイノベーションのための標準化されたアーキテクチャを作り上げました。中東・アフリカ地域では、文化的な敏感さやヘルスケアへのアクセスレベルの違いが、治療の状況に影響を与えています。アジア太平洋地域では、中国、日本、インドなどの国々が市場をリードし、PMSへの取り組みに対する認識と開放性が高まっています。中国とインドでは、伝統的な治療法とハーブ療法が依然として重要な位置を占めています。しかし、臨床的に承認された医薬品やホリスティックなウェルネス・アプローチへのシフトが進んでいます。特にインドと中国では、市場の潜在性の高まりを反映して、女性の健康に関する新興企業への投資が増加しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、月経前症候群治療薬市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、月経前症候群治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.月経前症候群治療薬市場の市場規模および予測は？

2.月経前症候群治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.月経前症候群治療薬市場の技術動向と規制枠組みは？

4.月経前症候群治療薬市場における主要ベンダーの市場シェアは？

5.月経前症候群治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 月経前症候群に関する診断の認知度向上
    • PMS治療製品をオンラインチャネルを通じて簡単に入手できる
  • 抑制要因
    • PMS医薬品および機器の製品リコールに関連する問題
  • 機会
    • PMS治療の進歩と新薬の登場
    • ウェアラブル技術の導入とデジタルヘルスの普及
  • 課題
    • PMS管理に関する社会的障壁と偏見
• 市場セグメンテーション分析
  • 薬剤の種類：避妊と症状管理の二重の役割を果たすことから、PMS症状の管理に経口避妊薬が利用されるようになってきています。
  • 流通チャネル：顧客の便利なショッピングニーズにより、eコマースの流通チャネルが好まれるようになっています。
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 月経前症候群治療薬市場薬の種類別

• 抗うつ薬
• 利尿剤
• 非ステロイド性抗炎症薬（NSAID）
• 経口避妊薬および卵巣抑制剤

第7章 月経前症候群治療薬市場：タイプ別

• 店頭
• 処方箋

第8章 月経前症候群治療薬市場：流通チャネル別

• eコマース
• 病院
• 小売薬局

第9章 南北アメリカの月経前症候群治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の月経前症候群治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの月経前症候群治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ビスタジェン、月経前不快気分障害の症状の急性期管理のためのPH80の探索的第2A相試験で良好な結果を発表
  • サーティ・マディソンは、ピル・クラブからの戦略的資産買収を通じて何千人もの患者に継続的なケアを提供し、女性の健康における地位を強化します。
  • ロンドンを拠点とするニューロテックのスタートアップ企業が月経症状用の医療機器を開発
• 戦略分析と提言

第13章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PREMENSTRUAL SYNDROME TREATMENT MARKET DYNAMICS
• FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 39. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 40. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 41. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 42. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 45. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 46. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 47. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 48. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 51. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 52. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 53. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 54. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 55. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 56. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 57. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 58. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 61. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 62. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 63. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 64. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 69. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 70. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 72. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 80. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 81. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 82. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 83. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 84. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 85. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 86. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 87. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 88. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 89. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 90. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 91. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 92. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 93. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 94. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 95. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 96. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 97. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 98. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 99. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 100. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 101. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 102. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 103. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 104. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 105. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 106. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 107. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 108. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 109. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 110. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 111. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 112. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 113. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 114. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 115. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 116. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 117. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 118. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 119. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 120. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 121. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 122. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 123. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 124. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 125. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 126. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 128. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 130. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 132. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 133. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 134. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 135. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 136. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 137. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 138. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 139. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 140. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 141. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 142. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 143. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 144. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 145. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 146. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 147. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 148. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 149. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 150. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 159. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 160. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 161. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 162. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 163. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 164. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 165. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 166. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 167. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 168. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 169. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 170. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 171. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 172. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 173. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 174. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 175. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 176. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 177. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 178. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 179. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 180. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 181. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 182. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 183. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 184. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 185. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 186. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 187. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 188. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 189. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 190. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 191. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 192. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 193. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 194. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 195. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 196. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 197. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 198. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 199. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 200. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 201. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 202. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 203. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 204. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 205. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 206. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 207. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 208. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 209. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 210. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 211. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 212. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 213. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 214. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 215. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 216. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 217. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 218. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 219. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 220. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 221. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 222. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 223. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 224. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 225. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 226. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 227. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 228. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 229. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 230. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 231. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 232. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 233. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 234. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 235. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 236. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 238. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 240. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 242. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 244. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 249. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 250. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 251. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 252. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 253. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 254. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 255. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 256. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 257. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 258. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 259. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 260. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 261. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 262. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 263. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 264. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 265. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 266. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 267. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 268. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 269. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 270. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 271. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 272. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 280. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 282. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 284. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 285. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 286. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

[192 Pages Report] The Premenstrual Syndrome Treatment Market size was estimated at USD 1.72 billion in 2023 and expected to reach USD 1.79 billion in 2024, at a CAGR 4.35% to reach USD 2.32 billion by 2030.

Premenstrual syndrome (PMS) comprises a range of physical, mental, and emotional changes or symptoms that occur in the few weeks before a woman's menstrual cycle. Symptoms may vary widely among women and can significantly impact daily functioning activities and quality of life. Treatment for PMS is thus multifaceted and personalized, aiming to alleviate specific symptoms and improve overall well-being. It ranges from lifestyle adjustments, dietary changes, and stress management to pharmacological interventions. Increased awareness and education about PMS and its impact on women's health and well-being and changing societal attitudes towards menstrual health and wellness have accentuated the need for comprehensive treatment options. Advances in medical research lead to more effective and personalized treatments, and government support for facilitating improvements in healthcare infrastructure and accessibility, including telehealth services, has encouraged more women to seek treatment. However, regulatory hurdles and safety concerns surrounding new and existing treatments may impede the widespread adoption of PMS treatment. Furthermore, variability in PMS symptoms and treatment efficacy makes standardized treatments challenging. However, key players are developing treatments that are tailored to individual genetic, hormonal, and lifestyle factors and researching effective natural, dietary, and lifestyle interventions that have fewer side effects. Creating digital platforms and apps for symptom tracking, therapy, and treatment plans can further boost the adoption of PMS treatment options among women,

Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management

Analgesics, particularly nonsteroidal anti-inflammatory drugs (NSAIDs), are an essential component in the pharmacological treatment of PMS as they are commonly used to alleviate physical discomfort and pain associated with PMS. These medications are effective in reducing cramps, breast tenderness, and muscle pain by inhibiting the production of prostaglandins, substances known to cause inflammation and pain. Selective serotonin reuptake inhibitors (SSRIs) represent prominent antidepressants prescribed for PMS management, specifically targeting emotional and mood-related symptoms. SSRIs increase the levels of serotonin in the brain, a neurotransmitter that can affect mood and social behavior. They are particularly useful for women experiencing severe pre-menstrual dysphoric disorder (PMDD), a more extreme form of PMS, and have shown efficacy in reducing irritability, mood swings, depression, and anxiety. Oral contraceptives (birth control pills) and ovarian suppression agents are frequently utilized in PMS and PMDD treatment. These medications work by regulating or suppressing ovulation and, therefore, hormonal fluctuations that can trigger PMS symptoms. Oral contraceptives, combined with estrogen and progestin, help in achieving hormone balance, reducing the severity of physical and emotional symptoms. Meanwhile, gonadotropin-releasing hormone (GnRH) agonists are another class of ovarian suppression agents that significantly reduce ovarian hormone production and are often used in severe cases of PMDD.

Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping

The e-Commerce platform has emerged as a significant distribution channel for premenstrual syndrome (PMS) treatment products. This channel facilitates easy access to a wide range of PMS treatment options available across the globe. Customers appreciate the convenience of browsing and purchasing products from the comfort of their own homes. Moreover, e-Commerce platforms often offer detailed product information, reviews, and comparisons, assisting consumers in making informed decisions. The ability to discreetly purchase and receive products enhances the appeal of this channel for individuals seeking PMS treatment options. Retail pharmacies remain a crucial distribution channel for PMS treatment products. This traditional channel allows consumers to obtain over-the-counter (OTC) and prescription medications with ease. Pharmacists play an integral role by providing professional advice, answering questions, and offering recommendations for managing PMS symptoms. The immediate availability of products and personal interaction with healthcare professionals make retail pharmacies a preferred choice for many individuals. In addition, retail pharmacies often stock a wide range of products and cater to various patient preferences and treatment requirements.

Regional Insights

In the Americas, the U.S. and Canada represent key nations for PMS treatment, characterized by high awareness and a strong focus on research and development in the pharmaceutical and medical sectors. The U.S. is notable for its diversity in treatment approaches, including over-the-counter (OTC) medications, prescription drugs, and natural supplements, representing the country's emphasis on personal choice and holistic health. Countries in the Americas witness ongoing investment in digital health solutions, such as mobile apps for PMS tracking and management. EU countries exhibit a strong preference for evidence-based medicine with a growing interest in natural and alternative treatments and a focus on advancing cutting-edge research in the realm of healthcare technology. There is a notable trend towards personalized medicine, leveraging genetic testing to tailor PMS treatment. Stringent regulations for the development and efficiency of medical devices, pharmaceutical preparations, and drugs in the EU have created a standardized architecture for innovations in the EU region. In the Middle East and Africa, cultural sensitivities and varying levels of healthcare accessibility impact the treatment landscape. The Asia Pacific region showcases a growing awareness and openness towards addressing PMS, with countries such as China, Japan, and India leading the market. Traditional remedies and herbal treatments still hold significant importance in China and India. However, there is an increasing shift towards clinically approved medications and holistic wellness approaches. Investment in women's health startups, particularly in India and China, has seen a rise, reflecting the growing market potential.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Premenstrual Syndrome Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Premenstrual Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Premenstrual Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Alfa Pharma GmbH, Asarina Pharma AB., ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma, Bayer AG, Cadila Pharmaceuticals., Comforte Cream by PMS4PMS, LLC, Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Mylan N.V., Par Pharmaceutical, Inc, Pfizer Inc., Samphire Neuroscience, Shine Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Himalaya Drug Company, and Vitane Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Premenstrual Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Type
  • Antidepressants
  • Diuretics
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Oral Contraceptives & Ovarian Suppression Agents

• Type
  • Over-the-Counter
  • Prescription

• Distribution Channel
  • E-commerce
  • Hospitals
  • Retail Pharmacies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Premenstrual Syndrome Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Premenstrual Syndrome Treatment Market?

3. What are the technology trends and regulatory frameworks in the Premenstrual Syndrome Treatment Market?

4. What is the market share of the leading vendors in the Premenstrual Syndrome Treatment Market?

5. Which modes and strategic moves are suitable for entering the Premenstrual Syndrome Treatment Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing awareness of diagnosis regarding premenstrual syndrome
    • 5.1.1.2. Easy availability of PMS treatment products through online channels
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with product recalls for PMS drugs and devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in therapy for PMS and the emergence of novel drugs
    • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
  • 5.1.4. Challenges
    • 5.1.4.1. Societal barriers and stigmatization regarding PMS management
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management
  • 5.2.2. Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Premenstrual Syndrome Treatment Market, by Drug Type

• 6.1. Introduction
• 6.2. Antidepressants
• 6.3. Diuretics
• 6.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• 6.5. Oral Contraceptives & Ovarian Suppression Agents

7. Premenstrual Syndrome Treatment Market, by Type

• 7.1. Introduction
• 7.2. Over-the-Counter
• 7.3. Prescription

8. Premenstrual Syndrome Treatment Market, by Distribution Channel

• 8.1. Introduction
• 8.2. E-commerce
• 8.3. Hospitals
• 8.4. Retail Pharmacies

9. Americas Premenstrual Syndrome Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Premenstrual Syndrome Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Premenstrual Syndrome Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
  • 12.3.2. Thirty Madison Delivers Continuity Of Care For Thousands Through Strategic Asset Purchase From The Pill Club, Strengthening Its Position In Women's Health
  • 12.3.3. London-Based Neurotech Start-Up Develops Medical Device For Menstrual Symptoms
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio